Eisai's Halaven to stay on UK Cancer Drugs Fund list pending reconsideration

11 March 2015

Japanese drug major Eisai (TYO: 4523) has announced that its drug Halaven (eribulin) will remain on the UK's National Cancer Drugs Fund in the UK pending reconsideration by the panel.

This is a result of appeals submitted by Eisai after NHS England decided to remove the drug, among others, from the list, and Halaven will remain available to patients pending the result of the reconsideration.

The drug is indicated for the treatment of patients with locally-advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimen for advanced cancer, which should have included an anthracycline and a taxane. It significantly improves overall survival in patients with advanced breast cancer after anthracycline and taxane treatment.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK